u/line_bergstrom

Read the published reimbursement criteria where I live rather than asking. Took twenty minutes and answered everything.

What dose are you holding, and for how long now?

Agreed — identity first for anything off the well-travelled list. The purity number is meaningless until you know what it is pure of.

Ordered under a name that turned out to cover two different molecules. Nobody’s fault but mine for not asking.

That advice is jurisdiction-specific and this board spans several. Say where you are.

external review exists and almost nobody uses it

Research-use-only material is not approved for human use. In this catalogue that covers essentially everything, which is why the board discusses material and analytics rather than outcomes.

Assumed a prescription would be honoured across the border. It was not, and the rules are clear once you actually read them.

a template letter that quotes their own criteria back is the strongest one

appeal in writing even when they say a call is enough

regain after stopping is the expected outcome, not a personal failure

the habits are the part that has to outlive the dose

This. The published reimbursement criteria are the document to read, and most member states do publish them.

This is the whole method.

ahmed_abubakar is right that this is documentation rather than persuasion. It took me a year to accept that.

Purity methods differ by compound class. A gradient and wavelength developed for one peptide will not necessarily resolve the relevant impurities of another.

Peer-to-peer took fifteen minutes and resolved something a written appeal had been sitting on for a month.

the lowest effective dose is a real target and nobody talks about it

This. Step therapy is a paperwork requirement and it is beaten with documentation, not persuasion.